TY - JOUR T1 - Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in plasma, antigenemia and mortality in COVID-19 patients JF - medRxiv DO - 10.1101/2021.03.08.21253121 SP - 2021.03.08.21253121 AU - María Martin-Vicente AU - Raquel Almansa AU - Isidoro Martínez AU - Ana P. Tedim AU - Elena Bustamante AU - Luis Tamayo AU - César Aldecoa AU - José Manuel Gómez AU - Gloria Renedo AU - Jose Ángel Berezo AU - Jamil Antonio Cedeño AU - Nuria Mamolar AU - Pablo García Olivares AU - Rubén Herrán AU - Ramón Cicuendez AU - Pedro Enríquez AU - Alicia Ortega AU - Noelia Jorge AU - Amanda de la Fuente AU - Juan Bustamante-Munguira AU - María José Muñoz-Gómez AU - Milagros González-Rivera AU - Carolina Puertas AU - Vicente Más AU - Mónica Vázquez AU - Felipe Pérez-García AU - Jesús Rico-Feijoo AU - Silvia Martín AU - Anna Motos AU - Laia Fernandez-Barat AU - Jose María Eiros AU - Marta Dominguez-Gil AU - Ricard Ferrer AU - Ferrán Barbé AU - David J Kelvin AU - Jesús F Bermejo-Martin AU - Salvador Resino AU - Antoni Torres Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/08/2021.03.08.21253121.abstract N2 - Purpose to evaluate the association between anti-SARS-CoV-2 S IgM and IgG antibodies with viral RNA load in plasma, the frequency of antigenemia and with the risk of mortality in critically ill patients with COVID-19.Methods anti-SARS-CoV-2 S antibodies levels, viral RNA load and antigenemia were profiled in plasma of 92 adult patients in the first 24 hours following ICU admission. The impact of these variables on 30-day mortality was assessed by using Kaplan-Meier curves and multivariate Cox regression analysis.Results non survivors showed more frequently absence of anti-SARS-CoV-2 S IgG and IgM antibodies than survivors (26.3% vs 5.6% for IgM and 18.4% vs 5.6% for IgG), and a higher frequency of antigenemia (47.4% vs 22.2%) (p <0.05). Non survivors showed lower concentrations of anti-S IgG and IgM and higher viral RNA loads in plasma, which were associated to increased 30-day mortality and decreased survival mean time. [Adjusted HR (CI95%), p]: [S IgM (AUC ≥60): 0.48 (0.24; 0.97), 0.040]; [S IgG (AUC ≥237): 0.47 (0.23; 0.97), 0.042]; [Antigenemia (+): 2.45 (1.27; 4.71), 0.007]; [N1 viral load (≥ 2.156 copies/mL): 2.21 (1.11; 4.39),0.024]; [N2 viral load (≥ 3.035 copies/mL): 2.32 (1.16; 4.63), 0.017]. Frequency of antigenemia was >2.5-fold higher in patients with absence of antibodies. Levels of anti-SARS-CoV-2 S antibodies correlated inversely with viral RNA load.Conclusion absence / insufficient levels of anti-SARS-CoV-2 S antibodies following ICU admission is associated to poor viral control, evidenced by increased viral RNA loads in plasma, higher frequency of antigenemia, and also to increased 30-day mortality.Take-home message absent or low levels of antibodies against the S protein of SARS-CoV- 2 at ICU admission is associated to an increased risk of mortality, higher frequency of antigenemia and higher viral RNA loads in plasma. Profiling anti-SARS-CoV-2 s antibodies at ICU admission could help to predict outcome and to better identify those patients potentially deserving replacement treatment with monoclonal or polyclonal antibodies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04457505Funding StatementThis work was supported by awards from the Canadian Institutes of Health Research, the Canadian 2019 Novel Coronavirus (COVID19) Rapid Research Funding initiative (CIHR OV2 170357) (DJK) and the Subvenciones de concesion directa para proyectos y programas de investigacion del virus SARS-CoV2, causante del COVID19, FONDO COVID19, Instituto de Salud Carlos III (COV20/00110, CIBERES, 06/06/0028), (AT) and finally by the Convocatoria extraordinaria y urgente de la Gerencia Regional de Salud de Castilla y Leon, para la financiacion de proyectos de investigacion en enfermedad COVID-19 (GRS COVID 53/A/20) (CA). APT was funded by the Sara Borrell Research Grant CD018/0123 funded by Instituto de Salud Carlos III and cofinanced by the European Development Regional Fund (A Way to Achieve Europe programme). The funding sources did not play any role neither in the design of the study and collection, not in the analysis, in the interpretation of data or in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Committee for Ethical Research of the coordinating institution, Comite de Etica de la Investigacion con Medicamentos del Area de Salud de Salamanca, code PI 2020 03 452.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOriginal data are available under reasonable request for scientist working in the field of COVID-19 ER -